Literature DB >> 19210160

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options.

Robert W Shafer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19210160      PMCID： PMC4764065          DOI： 10.1086/596737

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  21 in total

1.  Detection of minor populations of drug-resistant HIV-1 in acute seroconverters.

Authors:  Karin J Metzner; Pia Rauch; Hauke Walter; Christoph Boesecke; Bernhard Zöllner; Heiko Jessen; Knud Schewe; Stefan Fenske; Holger Gellermann; Hans-Jürgen Stellbrink
Journal:  AIDS       Date:  2005-11-04       Impact factor: 4.177

2.  Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.

Authors:  Laurence Morand-Joubert; Charlotte Charpentier; Gwendoline Poizat; Geneviève Chêne; Elisabeth Dam; Gilles Raguin; Anne-Marie Taburet; Pierre-Marie Girard; Allan J Hance; François Clavel
Journal:  Antivir Ther       Date:  2006

3.  Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.

Authors:  S Palmer; V Boltz; N Martinson; F Maldarelli; G Gray; J McIntyre; J Mellors; L Morris; J Coffin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

4.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.

Authors:  Denise Lecossier; Nancy S Shulman; Laurence Morand-Joubert; Robert W Shafer; Véronique Joly; Andrew R Zolopa; François Clavel; Allan J Hance
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

6.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sophie Le Coeur; Chureeratana Bowonwatanuwong; Pacharee Kantipong; Pranee Leechanachai; Surabhon Ariyadej; Prattana Leenasirimakul; Scott Hammer; Marc Lallemant
Journal:  N Engl J Med       Date:  2004-07-09       Impact factor: 91.245

7.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.

Authors:  Ingrid A Beck; Claudia Crowell; Robin Kittoe; Helba Bredell; Molefe Machaba; Carolyn Willamson; Wouter Janssens; Sabelle Jallow; Guido van der Groen; Yiming Shao; Mini Jacob; N M Samuel; Ivette Lorenzana de Rivera; Nicole Ngo-Giang-Huong; Sharon Cassol; George Alemnji; Lisa M Frenkel
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

10.  DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.

Authors:  Christian Hoffmann; Nana Minkah; Jeremy Leipzig; Gary Wang; Max Q Arens; Pablo Tebas; Frederic D Bushman
Journal:  Nucleic Acids Res       Date:  2007-06-18       Impact factor: 16.971
View more
  14 in total

1.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

2.  Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Authors:  Dongning Wang; Charles B Hicks; Neela D Goswami; Emi Tafoya; Ruy M Ribeiro; Fangping Cai; Alan S Perelson; Feng Gao
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.

Authors:  Jia Liu; Michael D Miller; Robert M Danovich; Nathan Vandergrift; Fangping Cai; Charles B Hicks; Daria J Hazuda; Feng Gao
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

4.  Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.

Authors:  Charlotte Hedskog; Mattias Mild; Johanna Jernberg; Ellen Sherwood; Göran Bratt; Thomas Leitner; Joakim Lundeberg; Björn Andersson; Jan Albert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

5.  Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory.

Authors:  Boaz Avidor; Shirley Girshengorn; Natalia Matus; Hadass Talio; Svetlana Achsanov; Irene Zeldis; Ilana S Fratty; Eugene Katchman; Tal Brosh-Nissimov; David Hassin; Danny Alon; Zvi Bentwich; Israel Yust; Sharon Amit; Relly Forer; Ina Vulih Shultsman; Dan Turner
Journal:  J Clin Microbiol       Date:  2013-01-02       Impact factor: 5.948

6.  Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

Authors:  Max Lataillade; Jennifer Chiarella; Rong Yang; Michelle DeGrosky; Jonathan Uy; Daniel Seekins; Birgitte Simen; Elizabeth St John; Elizabeth Moreno; Michael Kozal
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

7.  K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.

Authors:  Patricia Recordon-Pinson; Jennifer Papuchon; Sandrine Reigadas; Alaka Deshpande; Hervé Fleury
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

8.  Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.

Authors:  Lycely Del C Sepúlveda-Torres; Alexandra De La Rosa; Luz Cumba; Nawal Boukli; Eddy Ríos-Olivares; Luis A Cubano
Journal:  AIDS Res Treat       Date:  2012-04-24

9.  Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing.

Authors:  Vijay Bansode; Grace P McCormack; Amelia C Crampin; Bagrey Ngwira; Ram K Shrestha; Neil French; Judith R Glynn; Simon A Travers
Journal:  BMC Infect Dis       Date:  2013-01-30       Impact factor: 3.090

10.  Base-calling algorithm with vocabulary (BCV) method for analyzing population sequencing chromatograms.

Authors:  Yuri S Fantin; Alexey D Neverov; Alexander V Favorov; Maria V Alvarez-Figueroa; Svetlana I Braslavskaya; Maria A Gordukova; Inga V Karandashova; Konstantin V Kuleshov; Anna I Myznikova; Maya S Polishchuk; Denis A Reshetov; Yana A Voiciehovskaya; Andrei A Mironov; Vladimir P Chulanov
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.